Diane M. Simeone

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Figure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S4 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Table S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Table S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Table S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S6 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Figure S7 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

  2026-06-17

• Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the <scp>PRECEDE</scp> Consortium

  International Journal of Cancer · 2026-06-15

• AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.

  Journal of Clinical Oncology · 2026-05-27

• Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial.

  Journal of Clinical Oncology · 2026-05-27

• Pancreatic MRI Findings in High-Risk Individuals Compared with Matched Average-Risk Individuals

  Pancreas · 2026-05-11

• The integrated stress response promotes immune evasion through lipocalin 2

  Nature · 2026-02-18 · 8 citations

• Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux

  Cell · 2026-02-16 · 1 citations

• BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

  BMJ Oncology · 2026-01-01

• Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer

  JCI Insight · 2025-12-09 · 2 citations

• Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

  2025-11-24

• Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

  2025-11-24